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Objective: We investigated whether the level of vascular endothelial growth factor (VEGF), placental
growth factor (PlGF), and soluble VEGF receptor-1 (sFlt-1) in midtrimester amniotic ﬂuid of preterm birth
have different values compared with term delivery.
Materials and Methods: Our participants were 86 pregnant women who had undergone amniocentesis
from 16 to 19 weeks of gestation. Forty-three cases were women with preterm delivery, and the other 43
cases were matched women with full-term delivery. Stored amniotic ﬂuid was investigated after the
delivery. The levels of VEGF, PlGF, and sFlt-1 were measured by enzyme-linked immunosorbent assay
and Western blot.
Results: The levels of VEGF and PlGF in the preterm group were signiﬁcantly higher than in the control
group (30.48 ± 8.57 pg/mL vs. 26.06 ± 8.24 pg/mL and 28.83 ± 7.83 pg/mL vs. 25.35 ± 8.26 pg/mL,
respectively) (p ¼ 0.017 and 0.048, respectively). In terms of sFlt-1, the levels were decreased in the
preterm group (10,478.51 ± 4012.56 pg/mL vs. 12,544.05 ± 4140.96 pg/mL) (p ¼ 0.021).
Conclusion: This study explains that elevated levels of VEGF and PlGF, suggestive of angiogenesis and
tendency of inﬂammation at midtrimester, are predictive of preterm delivery, and their availability is
maximized by downregulation of sFlt-1.
Copyright© 2016, Taiwan Association of Obstetrics& Gynecology. Published by Elsevier Taiwan LLC. This is
anopenaccess article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Placental angiogenesis and vasculogenesis play an important
role for normal development of the fetus [1]. Altered angiogenic
marker expression has been studied in obstetric complications,
such as preeclampsia [2]. Increased levels of the angiogenic
markers like soluble fms-like tyrosine kinase-1 [soluble vascular
endothelial growth factor (VEGF) receptor-1, sFlt-1] or soluble
endoglin and lower levels of placental growth factor (PlGF) mayent of Obstetrics and Gyne-
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bstetrics & Gynecology. Published bpermit detection of preeclampsia before symptom onset [3,4]. The
relation between these angiogenic factors and preeclampsia seems
to be very strong and more predictive of risk for preeclampsia [5].
Another important complication during pregnancy is preterm
birth, which is deﬁned as delivery that occurs between 24 weeks of
gestation and 37 weeks of gestation [6]. Preterm delivery is
responsible for a signiﬁcant percentage of neonatal morbidity and
mortality. Based on the known risk factors and pathways of pre-
term birth, several biomarkers have been tested to see if they can
predict spontaneous preterm birth [7]. Relations between angio-
genic markers and preterm delivery have become important to
characterize the placental aspect associated with preterm labor or
the inﬂammatory role of angiogenic markers in pregnancy [8].
Little is known about angiogenic marker patterns in relation to
preterm delivery uncomplicated by preeclampsia. Preeclampsia-
like angiogenic marker changes have been reported late in preg-
nancy among spontaneous preterm labor cases; however, similar
changes occur in term pregnancies before labor onset [8].y Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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subset of spontaneous preterm delivery [8,9]. We measured mid-
pregnancy levels of VEGF and PlGF, as well as sFlt-1 in midtrimester
amniotic ﬂuid, and assessed their associations with preterm
delivery.Materials and methods
Study design
The research was designed to be a prospective study. Collection
of amniotic ﬂuid samples from January 2009 to June 2012 and
clinical data were approved by the Institutional Review Board of
Kosin Medical Center. All patients gave written informed consent,
in accordance with the Helsinki criteria. After excluding fetal an-
euploidies, anomalies, and cases who experienced pregnancy loss
within 30 days of amniocentesis, we enrolled and stored the
samples of amniotic ﬂuid for later analysis. Postdelivery patient
obstetric data were reviewed, and the clinical outcomes were ob-
tained. Gestational agewas determined based on the last menstrual
period and the ﬁrst trimester obstetric ultrasound evaluation
(crown rump length at 7e9 weeks). Preterm delivery was deﬁned
as birth before 37 weeks of gestation.Patients
A total of 596 pregnant women with singleton gestations un-
derwent amniocentesis and their samples of amniotic ﬂuid were
stored until delivery. Amniocentesis was carried out for proper
clinical indications (advanced maternal age, abnormal quad/triple
test, family history of chromosomal abnormalities, suspected fetal
anomalies or viral infection, and maternal request) at 16e19 weeks
of gestation. Among 596womenwith available samples of amniotic
ﬂuid, the study included 86 women for study objects. Patients were
invited to donate amniotic ﬂuid for research purposes. The clinical
outcome was obtained by chart review. Inclusion criteria were
uneventful pregnancy course before the procedure, absence of
congenital fetal malformations, absence of clinical signs of infec-
tion, normal volume of amniotic ﬂuid as assessed by ultrasound,
and healthy pregnant woman without chronic or medical disease.
Any preterm delivery associated with an obstetrical complication,
such as hypertensive disorders in pregnancy, obstetrical hemor-
rhage, fetal growth restriction, or premature rupture of the mem-
brane, was excluded from the amniotic ﬂuid analysis.
We retrieved samples from every case known to have resulted in
delivery before 37 weeks of gestation (n ¼ 43) and 43 control
samples fromwomenwho delivered at37 weeks of gestation. The
control samples were matched with the preterm group at a 1:1
ratio from sampling until testing (storage time). Matches were
based on maternal age, gestational age (weeks) at the time of
amniocentesis, and the indication for the procedure.Collection of amniotic ﬂuid and storage
Transabdominal amniocentesis was performed with a 21-gauge
needle under ultrasound guidance to evaluate the position of the
fetus. Amniotic ﬂuid was ﬁrst taken for further diagnostic testing,
depending on the indication of the invasive procedure. Afterward,
5 mL from a total volume of 20 mL of amniotic ﬂuid was collected
for research purposes. Samples were transported immediately to
the laboratory in a capped sterile syringe; amniotic ﬂuid samples
were then centrifuged for 10 minutes at 400 rpm and stored in
aliquots at 70C until analysis at the completion of follow-up.Enzyme-linked immunosorbent assay
Invitrogen assay kits (Carlsbad, CA, USA) were used for VEGF,
PlGF, and sFlt-1. These kits are based on the solid phase sandwich
enzyme-linked immunosorbent assay (ELISA) method. During the
ﬁrst incubation, samples were pipetted into wells coated with an-
tibodies speciﬁc for human VEGF, PlGF, and sFlt-1, followed by the
addition of a biotinylated secondary antibody. During the ﬁrst in-
cubation, the human antigen bound simultaneously to the immo-
bilized (capture) antibody on one site and to the solution phase-
biotinylated antibody on a second site.
After washing, streptavidin-peroxidase (enzyme) was added,
which binds to the biotinylated antibody to complete the four-
member sandwich. After a third incubation and wash to remove
any unbound enzyme, a substrate solution was added, upon which
the bound enzyme acts to produce color. The intensity of this
colored product is directly proportional to the concentrations of
VEGF, PlGF, and sFlt-1 present in the specimen. The coefﬁcients of
variation of intra-assay and interassay precision were 5.1e9.8% for
VEGF, 8.5e10.2% for PlGF, and 5.0e5.6% for sFlt-1, respectively. The
minimum detectable doses of VEGF, PlGF, and sFlt-1 were <5 pg/
mL, 1 pg/mL, and 2 pg/mL, respectively.
Western blot
A total of 1e2mL of amniotic ﬂuidwas prepared by dilutionwith
sodium dodecyl sulfate loading buffer (Fermentas, Waltham, MA,
USA), followed by boiling and cooling. The amniotic ﬂuid samples
underwent electrophoresis in a 13.5% sodium dodecyl sulfate-
polyacrylamide gel (Koma Biotech, Seoul, Korea). Thereafter, pro-
teins were electrotransferred to a polyvinylidene diﬂuoride mem-
brane (Millipore, Billerica, MA, USA) at 30 V for 1 hour. Nonspeciﬁc
binding was blocked for 1 hour in noise-cancelling reagents (Mil-
lipore). After washing, membranes were incubated for 2 hours at
room temperature with antibodies. The antibodies used (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) were rabbit antihuman VEGF
antibody (147) (CAT. # sc-507), goat antihuman PlGF antibody (C-
20) (CAT. # sc-1880), and mouse antihuman sFlt-1 antibody (C-20)
(CAT. # sc-315). A 5-bromo-4-chloro-3-indolyl-phosphate (BCIP)/
nitro blue tetrazolium (NBT) tablet (Sigma-Aldrich, St Louis, MO,
USA) dissolved in distilled water was used as growth substrate.
Chemiluminescence analysis was conducted with Luminata Cre-
scendoWestern HRP substrate (Millipore) and autoradiography ﬁlm
(Agfa-Gevaert, Mortsel, Belgium), according to the manufacturer's
instructions. The experiment was replicated three times. Bands
produced from the Western blot were shown using Gel Doc XRþ
with Image Lab software (Bio-Rad, Hercules, CA, USA).
Statistical analyses
Results are expressed as mean and standard deviation according
to the distribution of data. Kolmogorov-Smirnov's test was used to
evaluate the normality of the distribution of the continuous data.
Comparisons between the two groups were conducted using the
Student t test in a normal distribution and Х 2 test for univariate
analysis in the categorized variables. The receiver operating char-
acteristic (ROC) curve was applied to calculate each factor's predic-
tive value for preterm delivery. SPSS version 18.0 (SPSS Inc., Chicago,
IL, USA) was used for statistical calculations. A p value < 0.05 was
considered statistically signiﬁcant.
Results
A total of 43 patients delivered at <37 weeks of gestation; all
spontaneous preterm labors included an intact membrane. The
Table 2
Concentrations of VEGF, PlGF, and sFlt-1 measured by enzyme-linked immunosor-
bent assay in midtrimester amniotic ﬂuid of preterm and term groups.
Preterm delivery (n ¼ 43) Term delivery (n ¼ 43) p
VEGF (pg/mL) 30.48 ± 8.57 26.06 ± 8.24 0.017
PlGF (pg/mL) 28.83 ± 7.83 25.35 ± 8.26 0.048
sFlt-1 (pg/mL) 10,478.51 ± 4,012.56 12,544.05 ± 4,140.96 0.021
Results are expressed as mean ± standard deviation.
PlGF ¼ placental growth factor; sFlt-1 ¼ soluble VEGF receptor-1; VEGF ¼ vascular
endothelial growth factor.
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control group included 43 healthy pregnancies with full term de-
livery. Table 1 shows the clinical and demographic characteristics of
the study samples. There were no signiﬁcant differences between
the preterm delivery group and controls with respect to the
mother's age, the gestational age of the fetus at amniocentesis,
body mass index, neonatal sex, indication of amniocentesis, or
gravidity.
In comparing biomarkers between the preterm and full-term
groups, we found the following mean values: VEGF levels in the
amniotic ﬂuidwere 30.48 pg/mL and 26.06 pg/mL, respectively, and
PlGF levels in amniotic ﬂuid were 28.83 pg/mL and 25.35 pg/mL,
respectively. Both concentrations were signiﬁcantly different be-
tween the groups. By contrast, the levels of sFlt-1 were
10,478.51 pg/mL in the preterm group and 12,544.05 pg/mL in the
full-term group. This represents a signiﬁcant difference between
the groups (Table 2, Figure 1).
The above values were analyzed for their ability to predict
preterm birth using a ROC curve (Table 3, Figure 2). ROC analysis
was also used to determine the optimal amniotic ﬂuid levels for
VEGF, PlGF, and sFlt-1 that would predict preterm delivery. An
appropriate cut-off level for VEGF in amniotic ﬂuid was 25.25 pg/
mL, with a sensitivity of 76.7% and a speciﬁcity of 60.5%. For PlGF in
amniotic ﬂuid, the cut-off value was 23.80 pg/mL, with a sensitivity
of 76.7% and a speciﬁcity of 53.5%. Amniotic sFlt-1 levels had the
cut-off value of 11,666.00 pg/mL with the area under the curve of
0.629 in the consideration of the inversely rendered curve. Its
sensitivity and speciﬁcity were 62.8% and 55.8%, respectively.
Figure 3 shows the representative Western blot for preterm and
full-term groups showing levels of VEGF (55 kDa and 40 kDa,
respectively), PlGF (45 kDa), and sFlt-1 (110 kDa) in midtrimester
amniotic ﬂuid. The samples were randomly selected among the
participantsefour samples from the preterm delivery group and
four samples from the full-term delivery group. Amniotic ﬂuid from
the preterm delivery group showed thicker and darker bands of
VEGF and PlGF, but not of sFlt-1. The bands of sFlt-1 were more
prominent in the full-term delivery group.
Discussion
The data in this study indicate that the detection of angiogenic
factors in the midtrimester amniotic ﬂuid can provide a valuable
tool for the subsequently developed spontaneous preterm labor.
The set of VEGF, PlGF, and sFlt-1 values obtained in midtrimester
amniotic ﬂuid was investigated alongside the reference values in
the study. High concentrations of VEGF and PlGF were conﬁrmed inTable 1
Clinical and demographic characterizations of the participants.
Clinical characteristics Preterm delivery
(n ¼ 43)
Term delivery
(n ¼ 43)
p
Maternal age (y) 34.8 ± 4.3 34.2 ± 4.8 0.786
Gestational age at delivery (wk) 33.5 ± 1.8 39.5 ± 0.8 0.021
Gestational age at sampling (wk) 18.3 ± 0.2 18.0 ± 0.2 0.573
BMI (kg/m2) 21.7 ± 2.3 21.2 ± 1.5 0.562
Sex (male/female) 21/22 20/23 0.829
Gravidity 1.19 ± 0.45 0.98 ± 0.28 0.056
Indication for amniocentesis
Abnormal maternal serum markers 32 (74.4) 34 (79.1)
Increased nuchal translucency 2 (4.7) 1 (2.3)
Abnormal ﬁndings in ultrasound 0 (0) 1 (2.3)
Anomaly of previous baby 1 (2.3) 2 (4.7)
Pregnancy by IVF 4 (9.3) 3 (6.9)
Advanced maternal age 4 (9.3) 2 (4.7)
Results are expressed as mean ± standard deviation and n (%).
BMI ¼ body mass index; IVF ¼ in vitro fertilization.the spontaneous preterm group both with ELISA and Western blot
analysis. By contrast, the association between spontaneous preterm
labor and the lower level of sFlt-1 in midtrimester amniotic ﬂuid
was provided for the ﬁrst time.
Angiogenesis is essential for the development of the fetopla-
cental vascular network, as well as vasculogenesis [10]. In early
placental development, villous cytotrophoblasts produce a variety
of angiogenic factors, which induce the differentiation, prolifera-
tion, and migration of pluripotent mesenchymal cells via a para-
crine manner [11]. Secreted angiogenic factors activate angiogenic
cell cords causing further differentiation of endothelial precursor
cells. Pregnancy-speciﬁc growth factors and hormones, such as
human chorionic gonadotropin, a-fetoprotein, and insulin like
growth factor, may have a role in the ﬁne regulation of vascular
development of the fetoplacental unit [12]. Then, remodeling of
primary vessels occurs on extracellular matrix components. In this
process, vessel stabilization is supported by angiopoietin, its
respective receptors, VEGF, PlGF, nitric oxide (NO), vascular
endothelial-cadherin, and low oxygen [13]. Modiﬁcation of
placental vascular assembly may lead to subsequent obstetrical
pathologic conditions. Miscarriage, preterm birth, preeclampsia,
and intrauterine growth restriction may result from this patho-
physiologic cascade [14].
Evaluation of alterations in placental developments which can
threaten the obstetrical progress is not easy because of the difﬁ-
culty in obtaining living tissues. However, amniocentesis is pre-
formed easily with a very low risk of miscarriage in the early period
of gestation. Obtained amniocentesis samples may have informa-
tion of the angiogenic markers, which would be used to predict
subsequent obstetric complications. Even though the amniotic
membrane would only allow minimal transportation of high mo-
lecular angiogenic factors, the concentration of those molecules in
the amniotic ﬂuid may reﬂect the distribution in fetoplacental tis-
sues and maternal serum [15]. The levels of the molecules in am-
niotic ﬂuid are consistent with their site of production and local
tissue conditions. One other important source of high molecular
materials in amniotic ﬂuid is materno-embryonic transportation or
fetal production. The transportation to the amniotic cavity depends
on the molecular size, and as the amniotic membrane is almost
impermeable to large molecules, the fetal and maternal effects on
amniotic ﬂuid composition have been also considered [16].
For these reasons, we evaluated the levels of VEGF, PlGF, and
sFlt-1 as remarkable angiogenic factors in midtrimester amniotic
ﬂuid for the prediction of subsequent preterm birth. The angiogenic
markers VEGF and PlGF are abundantly expressed by the placenta
and several fetal tissues, and play key roles in the regulation of
effective vasculogenesis, angiogenesis, and placental development
[17,18]. Both VEGF and PlGF induce proliferation, migration, and
activation of endothelial cells, which they contribute to induction of
vascular permeability and maintenance of integrity of newly
formed blood capillaries. Failure to get the above adaptation may
result in reduced fetoplacental perfusion, associated obstetrical
complications like angiopoietin, fetal death, preeclampsia, and
preterm labor [19].
Figure 1. Concentrations of VEGF, PlGF, and sFlt-1 as measured by enzyme-linked immunosorbent assay in midtrimester amniotic ﬂuid in preterm and term delivery groups.
PlGF ¼ placental growth factor; sFlt-1 ¼ soluble VEGF receptor-1; VEGF ¼ vascular endothelial growth factor. group 0, preterm delivery; group 1, term delivery.
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and secreted from several different tissues, including human
endometrium, endothelial cells, and placental villous tissues [9,20].
Secreted sFlt-1 binds to VEGF and PlGF with high afﬁnity, thereby
decreasing their availability and acting as inhibitor of VEGF and
PlGF. Hypoxic condition is believed to induce the secretion of sFlt-1,
but the physiological signiﬁcance of the variable levels detected in
conception tissue is not yet fully understood [15]. During normal
pregnancy, sFlt-1 serum levels increase with advancing gestation,
but are markedly increased in both serum and placental tissue from
preeclamptic pregnancies [21]. Increased serum levels of sFlt-1 in
preeclampsia have been argued as a potential direct cause of
several manifestations of the disease, and it has been postulated
that in preeclampsia, the abnormal placentation following
placental hypoxia may result in increased sFlt-1 levels, thus
contributing to the pathogenesis of this disease [22]. Increases in
VEGF in maternal serum may be a trigger for elevation of placental
sFLT1 expression, which leads to preeclampsia. In addition,
placental sFLT1 has been regarded as having a role in placental
functions. Higher and earlier levels of sFlt-1 and PlGF were sug-
gested to have a decreased risk of adverse perinatal outcomes [23].
The association between the concentrations of sFlt-1 in amniotic
ﬂuid and the development of following preterm labor has not been
studied. As an antagonist of both VEGF and PlGF, it may play an
important role as antiangiogenic factor, and the prominent shift of
the levels in amniotic ﬂuid may also reﬂect the alteration of im-
plantation, placentation, pregnancy maintenance, and/or preg-
nancy termination. Mijal et al [5] reported that low sFlt-1 levels
were associated with preterm delivery unexplained by pre-
eclampsia and small for gestational age [5]. Unlike preeclampsia,Table 3
Receiver operating characteristic (ROC) analysis with the concentrations of VEGF,
PlGF, and sFlt-1 measured by enzyme-linked immunosorbent assay in midtrimester
amniotic ﬂuid.
Preterm delivery (n ¼ 43) vs. Term delivery (n ¼ 43)
Area
under
curve
95% CI p Cut-off
value
Sensitivity Speciﬁcity
VEGF
(pg/mL)
0.681 0.565e0.798 0.004 25.25 76.7 60.5
PlGF
(pg/mL)
0.635 0.514e0.756 0.032 23.80 76.7 53.5
sFlt-1
(pg/mL)
0.371 0.254e0.488 0.039 11,666.00 62.8 55.8
CI ¼ conﬁdence interval; PlGF ¼ placental growth factor; sFlt-1 ¼ soluble VEGF
receptor-1; VEGF ¼ vascular endothelial growth factor.representative of the hypoxic condition, relatively reduced levels in
amniotic ﬂuid for preterm birth were shown in this study. It is not
explained that the nonhypoxic condition of intraamniotic cavity is
related to the development of preterm labor. The molecular role of
sFlt-1 must be focused for its secondary play as a receptor for VEGF
and PlGF. sFlt-1 cannot act effectively in living tissues without some
molecules which bind with it, and decreased levels of sFlt-1 mean
the ampliﬁed action of VEGF and PlGF for the particular pathway.
The action may stand not only for angiogenesis or vasculogenesis,
but also for subclinical inﬂammation [24]. Thus, the detection of
sFlt-1 levels in amniotic ﬂuid can give information for preterm
birth, indirectly.
Now, it must be of concern why the proangiogenic proﬁles in
midtrimester amniotic ﬂuid are related to the subsequent sponta-
neous preterm labor without preeclampsia. In previous studies, the
relation between preterm birth and higher angiogenic markers has
become apparent in the cases of preeclampsia, small for gestational
age, or hypertensive conditions which may overlap or affect the
prevalence the preterm delivery [5,8,9]. However, in spontaneous
preterm birth, the association is not considered obvious without
obstetric complications. Brou et al [16] stated that maternally and
fetally derived intra-amniotic compartments showed cell-to-cell
interaction for both preponderant proinﬂammatory conditions
and angiogenesis, which are mutually dependent, in response to a
hostile environment. This may indicate the altered fetal/placental
growth and an innate immune response in reaction to a hostile
environment and preterm birth yet to happen [16,24]. Balanced
activity between these markers, which are detectable or undetect-
able in amniotic ﬂuid, may be nonexistent or active only to a lesser
degree, thereby inducing promotion of an adverse environment for
maintaining conception. The availability of biologically active mol-
ecules and their balance with regulatory molecules can determine
the ﬁnal outcome [25]. Therefore, understanding such environ-
ments and associatedmarkers canprovide the key for prediction for
preterm labor with risk assessment and management.
An authentic predictor of spontaneous preterm delivery is
clinically useful because it would allow for the identiﬁcation of
women at high risk of preterm birth, in whom a speciﬁc inter-
vention could be tested. The possibility to predict whichwomen are
likely to have a preterm birth is a prerequisite for the effective use
of most interventions aimed at preventing preterm birth. Also,
studies that identify predictors of spontaneous preterm birth may
be helpful to understand the mechanisms of biological pathways
and possibly lead to better interventions. Furthermore, they can
indicate predictive markers with noninvasive methods, unlike
amniocentesis. Finally, another reason for predicting preterm birth
is that being able to identify women with low risk would avoid
Figure 2. Receiver operating characteristic (ROC) curves that compare the values of VEGF, PlGF, and sFlt-1 for preterm delivery. PlGF ¼ placental growth factor; sFlt-1 ¼ soluble
VEGF receptor-1; VEGF ¼ vascular endothelial growth factor.
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both the initiation of preterm labor and the fetal complications
associated with prematurity by monitoring with technologies such
as cervical sonography and treating with interventions to reduce
the rate of preterm delivery.
This study provides an early demonstration of a possible pre-
term labor instigating association or interaction between angio-
genic biomarkers in amniotic ﬂuid. The concentrations measured
through ELISA were conﬁrmed by adjunctive Western blotting,
which is a widely accepted analytical technique used to detect
speciﬁc proteins in this type of tissue homogenate or extractFigure 3. Representative Western blot for preterm (Pt2*, Pt3*, Pt6*, and Pt7*) and full-
term (Pt1, Pt4, Pt5, and Pt8) groups showing levels of VEGF (55 kDa and 40 kDa,
respectively), PlGF (45 kDa), and sFlt-1 (110 kDa) in midtrimester amniotic ﬂuid.
PlGF ¼ placental growth factor; Pt ¼ patient; sFlt-1 ¼ soluble VEGF receptor-1;
VEGF ¼ vascular endothelial growth factor.(Figure 3). We evaluated the cut-off values for useful biomarkers to
predict preterm birth in midtrimester amniotic ﬂuid. The values
were 25.25 pg/mL, 23.80 pg/mL, and 11,666.00 pg/mL for VEGF,
PlGF, and sFlt-1, respectively. These levels cannot yet be applied in
clinical work and this is one of the limitations of this work; further
studies are needed to replicate and corroborate these results. There
seems to be variability in biomarker levels over time or between
individuals and races, making it difﬁcult to determine the threshold
level for risk of spontaneous preterm birth [25]. Indeed, the com-
bined use of markers has been shown to have better predictive
accuracy than individual markers alone because there are several
heterogeneous pathways that lead to spontaneous preterm birth
including inﬂammatory and angiogenic responses. The other limi-
tation is the lack of repeated angiogenic marker measurements
during pregnancy. Recent study has demonstrated the utility of
longitudinal measurements, showing stronger associations be-
tween changes in biomarker concentrations and preterm labor risk
[8].
This study has several strengths. The ﬁrst is thatwedid not know
or compare the levels of target molecules in the amniotic ﬂuid until
the termination of pregnancy. Another strength is the homogeneity
of the participant population, since it is a complex phenotype that is
related to multiple mechanisms, including infection/inﬂammation,
uteroplacental ischemia or hemorrhage, uterine overdistension,
stress, and other immunologically-mediated processes [26]. We
homogenized the pretermdelivery group by including only patients
with spontaneous preterm delivery <37 weeks of gestation in
singleton pregnancy.
S.E. Lee et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 539e544544This report concluded that it is feasible to measure the VEGF,
PlGF, and sFlt-1 concentrations in midtrimester amniotic ﬂuid for
the prediction of spontaneous preterm birth for asymptomatic
women. These angiogenic parameters can be useful and strong
biomarkers to distinguish high-risk patients and to discriminate
the expected preterm birth and to provide the understandable key
for the complex mechanism of preterm labor.
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